KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Capital Expenditures (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Capital Expenditures for 14 consecutive years, with $427000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 100.47% to $427000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, up 84.55% year-over-year, with the annual reading at $1.3 million for FY2025, 84.55% up from the prior year.
  • Capital Expenditures for Q4 2025 was $427000.0 at Supernus Pharmaceuticals, up from $129000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $851000.0 in Q1 2022, with the low at -$271000.0 in Q2 2022.
  • Average Capital Expenditures over 4 years is $201733.3, with a median of $200000.0 recorded in 2024.
  • The sharpest move saw Capital Expenditures tumbled 67.33% in 2023, then surged 691.67% in 2024.
  • Over 4 years, Capital Expenditures stood at -$168000.0 in 2022, then skyrocketed by 78.57% to -$36000.0 in 2023, then soared by 691.67% to $213000.0 in 2024, then surged by 100.47% to $427000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $427000.0, $129000.0, and $455000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.